Participant flow

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia · Source last updated 2024-03-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Standard VCR dosing (1.5 mg/m\^2, max 2 mg)

   id

   FG000

   title

   Regimen A: Standard Vincristine Dosing

2. description

   Intensive VCR dosing (2 mg/m\^2, max 2.5 mg)

   id

   FG001

   title

   Regimen B: Randomized High Dose Vincristine Regimen

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         9

      2. group Id

         FG001

         num Subjects

         3

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         7

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         2

      type

      Lost to Follow-up

   4. reasons

      1. group Id

         FG000

         num Subjects

         25

      2. group Id

         FG001

         num Subjects

         6

      type

      Physician Decision

   5. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         1

      type

      Withdrawal by Subject

   6. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         2

      type

      Entry onto another COG Trial

   7. reasons

      1. group Id

         FG000

         num Subjects

         11

      2. group Id

         FG001

         num Subjects

         5

      type

      Alternative Therapy

   8. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         0

      type

      Secondary Malignancy

   9. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Delay initiation

   10. reasons

       1. group Id

          FG000

          num Subjects

          26

       2. group Id

          FG001

          num Subjects

          10

       type

       Stem Cell Transplant

   11. reasons

       1. group Id

          FG000

          num Subjects

          18

       2. group Id

          FG001

          num Subjects

          9

       type

       Relapse

   12. reasons

       1. group Id

          FG000

          num Subjects

          4

       2. group Id

          FG001

          num Subjects

          1

       type

       Induction Failure

   Show more (12 of 15)

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         206

      2. group Id

         FG001

         num Subjects

         69

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         81

      2. group Id

         FG001

         num Subjects

         19

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         125

      2. group Id

         FG001

         num Subjects

         50

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice